C4 Therapeutics, Inc.（CCCC）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · CCCC · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$35.95M	$35.58M	$20.76M	$31.10M	$45.78M
Cost of Revenue	$7.97M	$0.00M	$7.74M	$0.00M	$0.00M
Gross Profit	$27.97M	$35.58M	$13.02M	$31.10M	$45.78M
Gross Margin %(computed)	77.81%	100.00%	62.72%	100.00%	100.00%
Operating Expenses
R&D Expenses	$104.24M	$110.64M	$117.71M	$117.84M	$94.67M
G&A Expenses	$36.20M	$42.12M	$42.08M	$42.79M	$33.25M
Total Operating Expenses	$132.46M	$155.20M	$152.05M	$160.63M	$127.92M
Operating Income	($104.49M)	($119.61M)	($139.03M)	($129.53M)	($82.13M)
Operating Margin %(computed)	-290.68%	-336.15%	-669.84%	-416.56%	-179.39%
Interest Income	$0.00M	$14.43M	$9.81M	$3.58M	$0.39M
Interest Expense	$0.00M	$0.00M	$1.37M	$2.22M	$2.15M
Income Before Tax	($104.87M)	($105.19M)	($131.21M)	($128.18M)	($83.89M)
Income Tax Expense	$0.12M	$0.13M	$1.28M	$0.00M	$0.00M
Net Income	($104.99M)	($105.32M)	($132.49M)	($128.18M)	($83.89M)
Net Margin %(computed)	-292.08%	-295.96%	-638.34%	-412.19%	-183.23%
Per Share & EBITDA
EPS (Basic)	$-1.27	$-1.52	$-2.67	$-2.62	$-1.82
Wtd Avg Shares	82.89M	69.37M	49.64M	48.86M	46.04M
EBITDA	($102.91M)	($103.37M)	($122.10M)	($124.28M)	($80.25M)
EBITDA Margin %(computed)	-286.29%	-290.49%	-588.28%	-399.68%	-175.29%